Donepezil Hydrochloride
Product Images NDC 63629-1117

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 63629-1117). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl636291117

This is a medication called Donepezil Hydrochloride, containing 23 mg that comes in a container with 30 tablets. The medication should be stored at 20° to 25°C and kept out of the reach of children. It is suggested to use a tight, light-resistant container with a child-resistant closure. The item has an NDC number of 63629-1117-1.*

FDA Label Image

Structural Formula (Spl Image1 Structure)

FDA Label Image

Figure 9 (Spl Image10 Figure9)

This is a table displaying the mean (with standard error) change from baseline in the ADCS-ADL for Donepezil Hydrochloride 10mg/day and Placebo groups after 3 months of drug treatment. There is also a comparison of clinical improvement vs clinical decline at baseline.*

FDA Label Image

Figure 10 (Spl Image11 Figure10)

FDA Label Image

Figure 11 (Spl Image12 Figure11)

This is a record of the SIB (Severe Impairment Battery) change from baseline after drug treatment. The drug used was either Donepezil Hydrochloride at a dose of 23mg per day or Donepezil Hydrochloride at a dose of 10mg per day. The clinical improvement observed was 5 to 7 percent after a few weeks of drug treatment.*

FDA Label Image

Figure 12 (Spl Image13 Figure12)

Cumulative Percentage of Patients for Donepezil HCI 23 mg/day and 10 mg/day treatment showing the change from Baseline. Data is presented in a graph format.*

FDA Label Image

Figure 13 (Spl Image14 Figure13)

This document seems to show a table related to the percentage of patients who took Donepezil Hydrochloride in different doses, along with a rating system called CIBICplus. The table shows various levels of improvement in the patients' condition after taking the medication. However, there seems to be some errors and missing information in the text, which can make the interpretation of the table challenging.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

FDA Label Image

Figure 2 (Spl Image3 Figure2)

FDA Label Image

Figure 3 (Spl Image4 Figure3)

FDA Label Image

Figure 4 (Spl Image5 Figure4)

This appears to be a graph or chart showing the ADAS-cog change from baseline for three different treatments (donepezil hydrochloride 10mg/day, donepezil hydrochloride 5mg/day, and placebo). The chart shows the mean Giincal Improvement and clinical decline over the course of 15 weeks of drug treatment. There is no further information available.*

FDA Label Image

Figure 5 (Spl Image6 Figure5)

FDA Label Image

Figure 6 (Spl Image7 Figure6)

This text is a table with percentages and medication dosages. It appears to be evaluating the effectiveness of different medications. However, the table is incomplete and difficult to interpret without additional context.*

FDA Label Image

Figure 7 (Spl Image8 Figure7)

This appears to be a table showing the mean change from baseline (in some measurement) after 4 and 12 months of clinical improvement, with a comparison between patients taking Donepezil Hydrochloride 10mg/day and patients taking a placebo. The exact nature of the measurement and the units are not clear from the provided text.*

FDA Label Image

Figure 8 (Spl Image9 Figure8)

The text appears to be a chart showing the cumulative percentage of patients who took Donepezil Hydrochloride 10 mg/day and the placebo in relation to their SIB (Severe Impairment Battery) Change from Baseline. Therefore, it is a medical analysis of a study.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.